Connaught-Squibb
Executive Summary
Firms modify their vaccine marketing agreement so that Connaught Labs will market directly all pediatric biologicals and vaccines and Squibb will continue to market Connaught's Fluzone influenza vaccine for adults and will have the option to market any other vaccines developed by Connaught for use in adults. Under a 1983 agreement, Squibb distributed some of Connaught's pediatric vaccines in the U.S. "The new arrangement allows Connaught to make further significant investments in its direct sales and distribution capabilities in the U.S. market," Connaught said.